At the 69th
Annual National Hemophilia Foundation Meeting in Chicago this morning, Pfizer announced the launch of 2 first-of-its-kind innovative technologies for patients living with the rare blood condition.
Hemocraft, a modified version of the video game Minecraft, and HemMobile Striiv Wearable, a custom wristband designed to assist people living with hemophilia better understand the disease and activity tracking throughout the country, will be on display at the meeting until its commencement on Saturday.
Hemophilia is a group of rare genetic bleeding conditions in which the body’s ability to produce a blood clot is either severely reduced or eliminated, and it can be fatal if not properly managed. There are 2 main types of the disease; hemophilia A, due to a deficiency in coagulating factor VII and hemophilia B, due to a deficiency in factor IX.
It affects approximately 20,000 people in the United States, and an estimated 400,000 people worldwide.
was developed in partnership with the Entrepreneurial Game Studio at Drexel University and representatives from the hemophilia community. The game intends to teach young hemophilia patients about the importance of integrating treatment into their daily routines while still having fun.
“We are excited to see fun and educational tools that help people with a bleeding disorder, but equally as important, their friends and family to better understand the concept of factor levels in being able to stay active, and stay in the game,” said Kate Nammacher, Senior Director of Education, National Hemophilia Foundation in a press release
The HemMobile Striiv Wearable is an easy-to-use, comprehensive tool that can be worn on thei wrist of a hemophilia patient. it contains features like the ability to monitor heart rate and activity levels, and it integrates with Pfizer’s existing HemMobile app (available in iTunes
and Google Play
), which allows users to log bleeds and infusions. Data captured can generate tailored reports to deliver insights to guide the discussion between a physician and their patient to the user’s care team.
“These new digital innovations can be integrated into everyday routines to help empower people with hemophilia to learn about and track different aspects relevant to their disease so that they can have informed conversations with their health care providers,” said Dr. Kevin W. Williams, Chief Medical Officer, Pfizer Rare Disease. “Ongoing innovation, coupled with our research, and support programs, continue to allow Pfizer to positively impact patients’ lives and pioneer a new era in hemophilia—today, and in the future.”
For more innovations from the rare disease community, follow Rare Disease Report